Impact of the COVID-19 Pandemic in Spain in the Successive Pandemic Waves on Hemodialysis Patients and Healthcare Personnel
-
Published:2023-06-28
Issue:13
Volume:12
Page:4337
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Mas-Fontao Sebastian12ORCID, Miranda-Serrano Blanca3, Hernán David3, López Raúl3, Manso Paula3, Dapena Fabiola3, Sánchez-Tocino Mº Luz3ORCID, Guerrero Jose3, Pereira Mónica3ORCID, Carneiro Damián3, Iglesias Adriana3, Piña Lola3, Guerrero Elena3, San Juan Marta3, Ledesma Cristina3, González Alicia3, Rossignoli Araceli3, Pereira Concepción3, Burgos Marina3, Sacristán Ana Mª3, González-Parra Emilio1ORCID, Arenas María Dolores3
Affiliation:
1. IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain 2. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, 28029 Madrid, Spain 3. Fundación Renal Íñigo Álvarez de Toledo, 28003 Madrid, Spain
Abstract
(1) Background: The impact of SARS-CoV-2 has been variable over the time course of the pandemic and in different populations. The aim was to analyze the impact of COVID-19 infection in a known population of hemodialysis (HD) patients and professionals in Spain at different times of the pandemic. (2) Methods: We conducted an observational, descriptive study with a follow-up from 3 March 2020 to 23 April 2022 (776 days), using in average of 414 professionals and 1381 patients from 18 HD units in Spain. The data from the positive PCR or the rapid antigen detection test (RADT) subject were analyzed and segmented into six periods (waves). (3) Results: Of 703 positive COVID-19 tests, 524 were HD patients (74.5%), and 179 were HD professionals (25.5%). Overall, 38% of staff and 43% of patients were affected. Differences were observed in regard to incidence (21% vs. 13%), mortality (3.5% vs. 0%), and symptomatology between the patients and professionals and throughout the pandemic. (4) Conclusions: COVID-19 severity varied during different pandemic waves, with a greater impact seen in the first wave. HD professionals and patients had similar infection rates, but patients had higher mortality rates. Community transmission was the primary route of infection.
Funder
Fundación Renal Íñigo Álvarez de Toledo Ministerio de Economia, Industria y competitividad: FIS/Fondos FEDER
Reference33 articles.
1. (2022, October 09). COVID-19. Available online: https://cnecovid.isciii.es/covid19/#evolución-pandemia. 2. Pulmonary infectious mortality among patients with end-stage renal disease;Sarnak;Chest,2001 3. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population;Sarnak;Kidney Int.,2000 4. Cardiovascular risk biomarkers in CKD: The inflammation link and the road less traveled;Elewa;Int. Urol. Nephrol.,2012 5. Chang, Y.T., Ling, T.C., Cheng, Y.Y., Sun, C.Y., Wu, J.L., Tai, C.H., Wang, J.R., and Sung, J.M. (2021). Comparison of Immunogenicity and Safety between a Single Dose and One Booster Trivalent Inactivated Influenza Vaccination in Patients with Chronic Kidney Disease: A 20-Week, Open-Label Trial. Vaccines, 9.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|